IRVINE, Calif., Dec. 22, 2010 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will conduct a 2011 guidance and pipeline update webcast/conference call after the market closes on January 5, 2011.
President and Chief Executive Officer, Vicente Anido, Jr., Ph.D., and Chief Financial Officer and Vice President of Corporate Development, Lauren Silvernail, will provide 2011 guidance, give a commercial and new product pipeline update, and highlight key milestones for 2011. The webcast/call will include a slide presentation; participants will be able to view the accompanying slides through ISTA's website. After the call, the slides will be available for download at http://www.istavision.com/investors.html under "Presentations".Date: Wednesday, January 5, 2011Time: 4:30 p.m. Eastern TimeWebcast and Conference Call Access:Internet: http://www.istavision.com/investors.html Domestic dial-in: 800-299-9086International dial-in: 617-786-2903Passcode: 69989701The webcast/conference call will be webcast live and archived on ISTA's website until February 2, 2011.
To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 57525060.
About ISTA Pharmaceuticals
ISTA Pharmaceuticals, Inc., is the fourth largest and fastest growing branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics. ISTA currently markets five products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The Company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain and nasal allergies. Headquartered in Irvine, California, the Company generated 2009 revenues of $111 million. For additional information about ISTA Pharmaceuticals, please visit the corporate website at www.istavision.com.
|SOURCE ISTA Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved